

CONTENTS

THE INFLUENZA VIRUS	2	AREAS OF PREDICTED AND POTENTIAL GROWTH	28
Viral make-up.....	2	The vaccination market - room for improvement?	28
Signs, symptoms, significance.....	3	Cell-derived vaccines - the new vaccine culture?	28
The influenza burden.....	3	Other avenues for improvement in anti-influenza interventions.....	29
Diagnosis difficulties.....	3	THE PANDEMIC INFLUENZA THREAT: IMPACT AND OUTLOOK	30
Viral subtypes - which influenza strain poses the biggest threat to human health?.....	4	Pandemic influenza - the facts	19
Shifting and drifting to survive.....	5	Potential impact of pandemic influenza on the market.....	30
H5N1 - a special mention.....	5	Evaluating industry and worldwide response to the pandemic threat	31
Viral targets for therapeutic intervention – Vaccination versus antivirals.....	6	Stockpile to survive.....	31
Vaccination.....	6	Country-by-country actions	32
Antivirals.....	7	Examining the effect on key influenza players	32
HISTORICAL PERSPECTIVES	8	The Tamiflu phenomenon	32
First reports.....	8	Relenza reaping the rewards	34
Pandemics in human history	8	Contracts galore.....	35
Epidemics.....	8	An outlook to the longer term	36
INDUSTRY INSIGHTS	9	What the future holds	36
Vaccine view – currently available and licensed products.....	9	The long-term legacy	37
Cell-cultured derived vaccines.....	9	The state of the pandemic today.....	37
Live attenuated vaccines.....	9		
Adjuvanted vaccines.....	9		
Currently available antivirals - an analysis of strengths and weaknesses	12		
M2 inhibitors versus neuraminidase inhibitors	12		
Investigating influenza vaccines and antivirals in the development pipeline	14		
Early efficacy indicators and market positioning pointers for developmental candidates.....	16		
Preclinical pipelines	19		
A broad outlook on future vaccine developments	22		
Reverse genetics	22		
DNA vaccines	22		
Mucosal adjuvants and delivery systems	22		
Recombinant vaccines	22		
KEY PHARMACEUTICAL PLAYERS: BAROMETERS OF PRESENT, PAST AND FUTURE SUCCESS	23		
Sanofi pasteur	23		
GlaxoSmithKline	23		
Chiron	24		
Global government endorsement	25		
AN EYE ON THE INFLUENZA MARKET: ANALYSING MARKET DIMENSIONS	26		
Current market size	26		
Disease impact	26		
Examining interventions	26		

Spotlight on Influenza – Separating Fact From Fiction in the Battle Against Influenza

ORDER FORM

FOR IMMEDIATE SERVICE PLEASE FAX THIS BACK TO: +44 (0) 1865 784 178

I would like to order copies of this report at the price of £495 / US\$845 / €745 each.

PAYMENT OPTIONS

INVOICE _____

CHEQUE (Please make cheques payable to PharmaVentures Ltd) (Sterling cheques must be drawn on a UK bank)

CREDIT CARD
Please debit my VISA AMEX MASTERCARD (Credit cards will be charged in £)

Card Number

Expiry Date (mm/yy)

Cardholder's Name: _____ Cardholder's Signature: _____
(Mr, Mrs, Ms, Dr please delete as applicable)

Position: _____

Company: _____

Cardholder's Address: _____

City: _____ Post/Zip code: _____

State/County: _____ Country: _____

Tel: _____ Fax: _____

E-mail: _____

From time to time we may pass your details to selected third parties whose products or services we believe would be of interest to you. This may include the transfer of information to companies outside the EEA. If you do NOT wish your details to be passed on, please tick this box. **WEB**

BANK TRANSFER - Please make payable to:

National Westminster Bank, 121 High Street, Oxford, OX1 4DD, UK

A/C Number Sterling: 84207515, A/C Number Euros: 06875599, Sort Code: 60-70-03

A/C Number Dollars: 140/00/06577547, Sort Code: 60-76-41, Swiftcode: NW BK GB 2L

Please fax a confirmation of your bank transfer to +44 (0) 1865 784 178. Payment is required prior to delivery.

EU Members States VAT registration No: _____

Please note: In the UK, printed matter is zero rated for VAT.

PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA, UK
Tel: +44 (0) 1865 784 177
Fax: +44 (0) 1865 784 178
E-mail: enquiries@pharmaventures.com
Web site: www.pharmaventures.com

 **PharmaVentures**
Experts in deals and alliances